Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis -a multicenter collaborative double blind study-

Abstract The effect of a new inhibitor of platelet aggregation, ticlopidine, at a daily oral dose of 200mg, was investigated on prevention of thrombotic obstruction of the arterio-venous shunts or vascular grafts in 107 uremic patients under chronic hemodialysis: the patients were those who had suffered from frequent thrombotic episodes in their blood accesses. The study was conducted in a double blind fashion with an inactive placebo. Frequency of clot removal was significantly (p